GLP-1 and Running: Endurance Training, Pace and Fuelling

If your easy runs have started feeling like tempo runs while the watch says you are going the same speed or faster, you are experiencing two effects pulling in opposite directions. Carrying less mass makes any given pace cheaper in absolute oxygen terms. Running on a sustained energy deficit with less reliably topped-up glycogen, and with a resting heart rate a few beats above where it used to sit, makes that same pace feel more expensive. The randomised data are blunt about the part people most want to be true: cardiorespiratory fitness did not improve from the drug alone. It improved in the arms that trained.

What happens to VO2peak with and without training

A secondary analysis of the S-LITE randomised trial measured VO2peak relative to fat-free mass across four arms. It rose about 10% in the exercise group and in the combined exercise-plus-drug group. In the GLP-1-alone group it did not improve significantly.

Comparing the combined arm against the drug-alone arm, peak oxygen consumption was 3.0 mL/min/kg of fat-free mass higher and stair-climb time was 1.2 seconds faster. The exercise participants were doing a median of about 2.65 sessions a week, roughly 108 minutes of moderate-to-vigorous activity. That is not a heavy programme, and it produced the entire fitness difference.

This matters because losing weight can look like getting fitter. Your 5k time drops. Hills that used to hurt do not. What has changed is the mass being transported, not the engine transporting it. If you stop training and rely on the drug, the scale will keep moving and your aerobic capacity will not.

Why pace can improve while the effort feels worse

Running economy is partly a mass problem. Move 8 kg less and the same pace demands less absolute oxygen, which is why the watch reports improvement.

Perceived effort is a different system. Endurance work above roughly 60 to 70% of VO2max is glycogen-sensitive, and a sustained energy deficit means muscle and liver glycogen are less consistently full. You are running the same speed on a smaller tank. Add a resting heart rate sitting 1 to 4 bpm higher than your pre-treatment baseline and every heart-rate reading during the run reads slightly elevated as well.

The mismatch is not in your head, and it is not evidence that something is wrong. It is what a deficit feels like from inside a running shoe.

Heart-rate zones set before you started are now slightly wrong

The Wegovy prescribing information documents mean resting heart rate increases of 1 to 4 bpm versus placebo in the weight-management trials. Every zone model you own was built on a baseline that has shifted.

Four beats is small in absolute terms and large in relative terms if your zone-two ceiling is a 12-beat-wide band. In practice people find themselves capped out of the bottom of zone two on runs that used to sit comfortably inside it, then slow down further, then get frustrated.

Many coaches re-test zones once titration has settled rather than assume the old numbers still hold. That is a straightforward fix. What it does not fix is glycogen availability, so expect the re-tested zones to still feel harder than they used to at the same pace.

Fuelling a long run when gastric emptying is delayed

This is the endurance-specific problem and it is mechanical rather than metabolic. GLP-1 receptor agonists delay gastric emptying, an effect the labelling describes as largest after the first dose and after each dose escalation, diminishing over time. The same mechanism that produces fullness also slows the arrival of anything you swallow.

For a runner that means the gel taken at 60 minutes may not be doing work at 75 minutes the way it used to. It may still be sitting in your stomach at 90 minutes, which is its own problem during a hard effort when blood flow has been diverted away from the gut. Carbohydrate that has not left the stomach is not fuelling anything and is instead sloshing.

Liquid and gel carbohydrate is often tolerated better than solid food when emptying is slowed, but that is a tolerance observation rather than a rule, and tolerance varies enormously between people. The one thing that generalises: this is a thing to test in training, and specifically to re-test during titration weeks, rather than to discover on race morning.

• The delay is largest after the first dose and after each escalation, then diminishes
• Anything taken by mouth is affected, which includes drinks and electrolyte tablets, not only gels
• Nausea was reported by about 44% of semaglutide 2.4 mg participants in STEP 1 and 31 to 43% of tirzepatide participants in SURMOUNT-1, concentrated in escalation
• Fuelling strategies that worked before treatment are commonly re-tested during titration rather than assumed
• A long run is a bad place to find out how a new fuelling approach behaves

Easy running and hard efforts are affected differently

Easy running sits mostly on fat oxidation and is less glycogen-dependent, so it survives a deficit better than intervals do. What degrades it is perceived effort, driven by the elevated heart rate and by generally lower energy availability. The run is doable, it just feels ungenerous.

Hard efforts are where the deficit bites properly. Anything above threshold draws on muscle glycogen, and glycogen is exactly what is less reliably topped up. Sessions may start well and fall apart late. Repeat quality across an interval set is often the first thing to go.

Gut tolerance also splits along the same line. Blood flow to the stomach falls as intensity rises, so a delayed-emptying stomach is far more noticeable at 5k pace than on a shuffle. People frequently report that easy running is fine and that hard running is where the GI symptoms show up.

Heat, dehydration and the warning on the label

FDA labelling across the class warns of serious kidney injury following dehydration, in some cases severe enough to require haemodialysis, with most reported cases following nausea, vomiting or diarrhoea. Labelling advises monitoring renal function in patients who have reactions that could cause severe dehydration.

Endurance running in heat is, by design, a controlled dehydration exercise. Stack it on top of a GI-upset week and you have combined the two halves of the label warning deliberately. That specific combination, a long session in heat during or just after a run of vomiting or diarrhoea, is the one to treat as a reason to shorten the session rather than to push through it.

Nothing here says do not run in summer. It says the margin is thinner than it was, and the failure mode at the end of it is a kidney problem rather than a bad workout.

Fluid intake is worth a thought of its own, because the same delayed gastric emptying that slows carbohydrate also slows water leaving the stomach. Drinking to the old schedule can leave more of it sitting there than it used to.

Lean mass, running economy and injury risk during rapid loss

Trial data without a structured training programme put lean soft tissue at roughly 25 to 40% of total weight lost. Runners lose the same way as everyone else, and running is not resistance training. It provides very little of the loading signal that biases a deficit toward fat.

That is the argument for keeping strength work in the week even while marathon training, which is an argument that predates GLP-1s and is only sharpened by them. Two sessions a week is the volume with randomised evidence attached in this population.

Rapid weight change also alters the mechanics you have adapted to over years, at the same time as tendons and bones are adapting on a much slower timescale than fat mass is disappearing. The sensible read is to treat a period of fast loss as a period for holding training load steady rather than building it. See the dedicated page on training and lean mass for the numbers.

Dose days, titration weeks and racing

No trial has tested where in the dosing cycle to put a hard session. GI adverse events cluster in the escalation phase, and delayed gastric emptying peaks after each increase, so the 24 to 48 hours after an injection are commonly reported as the roughest window during titration. Many people move the demanding sessions away from it. Whether that suits your dosing schedule is a question for your prescriber, not something to rearrange unilaterally.

For an event, the useful framing is that a titration week is a bad week to race and a worse week to try a new fuelling plan. Once doses are stable the gastric-emptying effect diminishes, which is the point at which whatever you have practised in training is most likely to behave the same way on the day.

A first-person account, for context

Everything above is drawn from trial data and prescribing information. What that evidence cannot give you is what a GLP-1 block actually feels like week to week in someone training seriously.

Thomas Prommer, a competitive endurance athlete, has written up what happened to his race results across a GLP-1 block. Read it as one person's experience rather than as evidence. It is n=1, it is uncontrolled, and it describes an athlete population the trials on this page did not study. It is useful for exactly that reason and for no other.

The evidence, one row per claim

Sources

1. Physical Fitness with Exercise and GLP-1 RA Treatment Alone or Combined (Sports Medicine)
2. Jensen et al., secondary analysis of S-LITE (PubMed)
3. WEGOVY (semaglutide) US Prescribing Information, FDA
4. MOUNJARO (tirzepatide) US Prescribing Information, Eli Lilly
5. Rubino et al., GI tolerability across SURMOUNT-1 to -4 (Diabetes Obes Metab)
6. OZEMPIC (semaglutide) US Prescribing Information, FDA

Keep reading

• GLP-1 and Heart Rate: The Resting Increase and What SELECT ShowedThe heart-rate rise is real, labelled and small. The outcome trial found a 20% reduction in major cardiovascul
• GLP-1 and Endurance Event FuellingEndurance fuelling depends on the one thing this drug class slows. The conflict is real, the label documents t
• GLP-1 and Doping: WADA Status of Semaglutide and TirzepatideThe question has two answers and most coverage gives only the first. An approved GLP-1 is not banned. An unapp
• GLP-1 and Hydration: Why Fluid Intake Drops and Why It MattersA soft wellness topic with a hard regulatory warning behind it: dehydration following GI symptoms is the docum
• GLP-1 and Working Out: Strength Training, Muscle Loss and ProteinLean mass loss is real and measured. The trials that measured it mostly had nobody lifting, so treat those num
• GLP-1 and Energy: Fatigue, Gym Performance and What Causes ItFatigue on a GLP-1 usually has a findable cause. Separate the fixable from the expected instead of accepting i